🇺🇸 DEA Invites Only Opponents to Participate in Marijuana Rescheduling Hearing

The Drug Enforcement Administration has selected participants for an upcoming hearing on federal marijuana rescheduling but has reportedly invited only opponents of the reform to take part, raising concerns about fairness and balance in the process. The hearing is a key step in determining whether cannabis will be moved from Schedule I to Schedule III, a change that could significantly impact federal policy, research and industry operations. Critics argue that excluding supporters from participation could skew the proceedings and undermine confidence in the review, while highlighting ongoing tensions surrounding the federal government’s approach to cannabis reform. (Marijuana Moment)

🚫 Federal Judge Blocks Ohio Hemp Restrictions in Temporary Ruling Favoring Businesses

A federal judge has granted a temporary restraining order to 10 hemp companies in Ohio, preventing the state from enforcing a new law that restricts federally legal hemp products to licensed cannabis operators, at least for 14 days. The lawsuit argues the law unfairly discriminates against out‑of‑state businesses and violates interstate commerce protections by effectively criminalizing products that remain legal under federal law. The ruling allows the companies to continue operating under federal hemp guidelines for now, while the broader legal challenge could determine whether states can impose stricter rules ahead of upcoming federal restrictions. (Cannabis Business Times)

🌿 Federal Marijuana Rescheduling May Not Apply to Washington State Cannabis Businesses

Washington state regulators say the federal move to reschedule medical marijuana to Schedule III likely does not apply to businesses in the state due to its unique system that primarily regulates cannabis as a unified recreational market rather than through a distinct medical licensing framework. Because Washington does not issue separate medical cannabis licenses, many operators may not qualify for federal registration or benefits tied specifically to “state‑licensed medical” programs. Officials emphasize that guidance is still evolving, but the situation highlights how differences in state regulatory structures could limit the impact of federal reform and create uneven benefits across the cannabis industry.

👉 Read The Full Study Here

🧬 Cannabis Terpenes Show Promise for Pain Relief Without Psychoactive Effects

A new study reported by ScienceDaily found that certain cannabis‑derived terpenes, natural compounds responsible for the plant’s aroma, may significantly reduce chronic pain without causing the “high” associated with THC. Researchers observed notable pain relief in preclinical models of fibromyalgia and post‑surgical pain, with one compound, geraniol, showing particularly strong effects. The findings suggest these non‑intoxicating components could represent a promising new direction for pain management treatments, especially for patients seeking alternatives to traditional cannabis or opioids. (ScienceDaily)

🗓️ Continued Cannabis News & Events

• Weeding Through the True Cost of Building a Cannabis Market to Balance the Budget

• NC Senate Democrats propose legalizing cannabis, but prospects hazy

• German Advocates: Cannabis Flowers Are Necessary For Medical Care

• Ukraine Issues First Medical Cannabis Prescriptions, Two Years After Legalisation